Rheosorbilact®; Ringer lactate
Проводит Yuria-Pharm
Страница компанииOpen-label, Randomized, Controlled, With Blind Assessor, Study to Assess Efficacy and Safety of Rheosorbilact®, Solution for Infusion ("Yuria-Pharm"), in Comparison With Ringer's Lactate,Solution for Infusion, in a Complex Therapy of Burns
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–60 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 118 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (05.2021) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 35 · невключение: 7
Критерии включения
- Male and female aged 18 to 60 years inclusive
- Thermal damage of 2nd stage with a total area of at least 20% and not more than 45% of the body surface.It is acceptable to include patients with deep burns, with a total area from 3% to 15% of the body surface in combination with superficial burns or isolated.
- Severity of state according to the Frank index from 30 to 90.
- The duration of the resulting thermal injury no more than 3 days from the planned first administration of the drug
- Informed consent for participation in the study signed by subject's own hand.
- Non-inclusion Criteria:
- Individual intolerance to components of the study drug and the comparator;
- Hypersensitivity to sodium lactate;
- Intravenous infusions of lactate- or sorbitol-containing products within 24 hours before enrollment;
- Pregnancy or breast-feeding;
- Severe renal dysfunction (creatinine is more than 300 μmol/l or estimated creatinine clearance is less than 30 ml/min);
- Metabolic alkalosis;
- Severe metabolic acidosis;
- Intracerebral hemorrhage;
- Any thromboembolism;
- Decompensated cardiovascular failure;
- Blood hypertension, grade III (SBP ≥ 180 mm Hg and/or DBP ≥ 90 mm Hg);
- Conditions associated with immunodeficiency (use of cytotoxic drugs or systemic steroids, AIDS, diabetes mellitus);
- Extracellular hyperhydration or hypervolemia;
- Severe renal insufficiency (with oliguria/anuria);
- Hyperkalemia;
- Hypercalcemia;
- Ascites associated with cirrhosis;
- Conditions associated with increased lactate levels (hyperlactatemia > 2 mmol / l), including lactic acidosis, or impaired lactate uptake (including due severe hepatic insufficiency);
- Concomitant therapy with cardiac glycosides.
- The need for artificial ventilation
- The presence of HIV or other immunodeficiency conditions
- Diabetes mellitus type I or type II with the need for insulin;
- The need for hemodialysis or other methods of extracorporeal detoxification
- Conducting chemotherapy now or within 60 days before enrollment
- Continuous use of corticosteroids in any form in a dose exceeding the equivalent of 10 mg of prednisolone per day
- The total burn area is less than 20% or more than 45% of the body surface
- The presence of deep burns (3 degrees and higher in the ICD-10).
- Localization of burns in areas that interfere with the infusion of the test drug.
- The severity of the state according to the Frank index is less than 30 and more than 90 units
Критерии невключения
- Infusion of the study drug or the comparator is started more than 12 hours after randomization;
- Withdrawal of the informed consent by the subject;
- Investigator considers that the infusion therapy with either study drug or comparator may not be continued for safety reasons;
- Development of conditions that prevent further use of the study drug/comparator before efficacy evaluation visit (Visit 3);
- Subject needs concomitant therapy prohibited in the study before efficacy evaluation visit (Visit 3);
- Development of conditions (including serious adverse events) which make it impossible to evaluate the primary endpoint;
- Confirmation of pregnancy at any time of the study.
Источник: ClinicalTrials.gov, NCT04152096 · запись обновлена в реестре 10 марта 2025.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 37
- A change in the total SOFA score vs. baseline score upon admission — Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Цель исследования
This study evaluates the efficacy and safety of Rheosorbilact®, solution for infusion ("Yuria-Pharm" LLC), in comparison with Ringer's Lactate, solution for infusion, in a complex therapy of burns. Half of participants will receive Rheosorbilact® in complex therapy, while the other half will receive Ringer's Lactate in complex therapy.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT04152096 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.